ASSET PURCHASE AGREEMENT dated as of July 23, 2012, by and between PRECISION BIOLOGICS, INC., as Purchaser, and NEOGENIX ONCOLOGY, INC., as SellerAsset Purchase Agreement • July 26th, 2012 • Neogenix Oncology Inc • In vitro & in vivo diagnostic substances • Maryland
THIS ASSET PURCHASE AGREEMENT is dated July 23, 2012 (the “Execution Date”), by and between Precision Biologics, Inc., a Delaware corporation (“Purchaser”) and Neogenix Oncology, Inc., a Maryland corporation (“Seller”).
BRIDGE LOAN NOTEBridge Loan Note • July 26th, 2012 • Neogenix Oncology Inc • In vitro & in vivo diagnostic substances
FOR VALUE RECEIVED, the undersigned NEOGENIX ONCOLOGY, INC., a Maryland corporation (the "Borrower"), hereby promises to pay to the order of PRECISION BIOLOGICS, INC., a Delaware corporation (together with its successors or assigns, the “Lender”), at such office as Lender may direct, in lawful money of the United States and in immediately available funds, the principal amount of SIX HUNDRED FORTY THOUSAND SIX HUNDRED NINETY-SEVEN AND NO/100 DOLLARS ($640,697.00), together with interest thereon and other agreed charges as provided herein.
